Pancreatic Cancer Research

ResearcherJapan Agency for Medical Research and DevelopmentActive in the last 2 years

Kazuaki Shimada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0613-4953; OpenAlex author ID A5101718133, A5110775037. Sources: OpenAlex.

Their work

Papers
32 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 3 papers · 2015: 4 papers · 2016: 5 papers · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 32

  1. Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. Last author DOI 10.1002/ags3.12753↗
  2. Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. Co-author DOI 10.1007/s00535-023-02033-3↗
  3. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Co-author DOI 10.1038/s41416-021-01639-9↗
  4. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Last author DOI 10.1245/s10434-022-11950-1↗
  5. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Last author DOI 10.1245/s10434-022-11957-8↗
  6. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  7. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  8. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0242851↗
  9. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. Last author DOI 10.1002/bjs5.50130↗
  10. ASO Author Reflections: Clinical Significance of Further Subdivision of N Staging in Pancreatic Cancer. Last author DOI 10.1245/s10434-019-07918-3↗
  11. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Co-author DOI 10.18632/oncotarget.26646↗
  12. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Co-author DOI 10.1007/s00535-018-1466-y↗
  13. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envel… Co-author DOI 10.1053/j.gastro.2017.03.050↗
  14. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  15. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
  16. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00428-016-2026-6↗
  17. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  18. Prevalence and predictive factors of depression and anxiety in patients with pancreatic cancer: a longitudinal study. Co-author DOI 10.1093/jjco/hyv169↗
  19. Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000574↗
  20. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. Co-author DOI 10.1186/s12876-016-0503-7↗
  21. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Last author DOI 10.1038/bjc.2015.145↗
  22. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Co-author DOI 10.1038/srep17018↗
  23. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Co-author DOI 10.1038/srep18425↗
  24. A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile. Co-author DOI 10.1371/journal.pone.0132223↗
  25. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ctg.2014.5↗
  26. Knowledge discovery for pancreatic cancer using inductive logic programming. First author DOI 10.1049/iet-syb.2013.0044↗
  27. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. Co-author DOI 10.7314/apjcp.2014.15.1.391↗
  28. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Co-author DOI 10.1038/bjc.2013.32↗
  29. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055146↗
  30. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  31. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Co-author DOI 10.1245/s10434-011-2020-9↗
  32. Total pancreatectomy with en bloc celiac axis resection for a pancreatic adenocarcinoma involving both the gastroduodenal artery and the celiac artery. Co-author DOI 10.5754/hge11687↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobuyoshi Hiraoka · 17 shared papers, 2013–2022 · strength 1.42
  2. Satoshi Nara · 12 shared papers, 2012–2024 · strength 1.25
  3. Minoru Esaki · 10 shared papers, 2012–2024 · strength 1.05
  4. Yoshinori Ino · 9 shared papers, 2013–2022 · strength 0.74
  5. Takuji Okusaka · 10 shared papers, 2012–2023 · strength 0.65
  6. Takeshi Takamoto · 3 shared papers, 2022–2024 · strength 0.54
  7. Daisuke Ban · 3 shared papers, 2022–2024 · strength 0.54
  8. Yoji Kishi · 5 shared papers, 2012–2022 · strength 0.45
  9. Chigusa Morizane · 6 shared papers, 2012–2018 · strength 0.32
  10. Tomoo Kosuge · 8 shared papers, 2012–2016 · strength 0.32
  11. Shunsuke Sugawara · 2 shared papers, 2022 · strength 0.30
  12. Kei Kitamura · 2 shared papers, 2022 · strength 0.30
  13. Noriteru Doi · 2 shared papers, 2020–2022 · strength 0.28
  14. Shutaro Hori · 3 shared papers, 2016–2020 · strength 0.27
  15. Masafumi Ikeda · 3 shared papers, 2012–2023 · strength 0.26
  16. Ryo Saito · 1 shared paper, 2024 · strength 0.24
  17. Tatsuya Ioka · 2 shared papers, 2016–2023 · strength 0.23
  18. Mari S. Oba · 1 shared paper, 2023 · strength 0.18
  19. Akio Saiura · 1 shared paper, 2023 · strength 0.18
  20. Erina Takai · 3 shared papers, 2015–2018 · strength 0.18
  21. Shinichi Yachida · 3 shared papers, 2015–2018 · strength 0.18
  22. Daisuke Asano · 1 shared paper, 2019 · strength 0.16
  23. Hideyuki Hayashi · 3 shared papers, 2015–2017 · strength 0.16
  24. Makoto Ueno · 4 shared papers, 2014–2016 · strength 0.15
  25. Mami Takahashi · 4 shared papers, 2014–2016 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.